about
Update on treatment of light chain amyloidosisRationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisStanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicityRenal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis.A patient with AL amyloidosis with negative free light chain results.Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult.A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosisAnalysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment.Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli.Clinical aspects of systemic amyloid diseases.Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.The workings of the amyloid diseases.A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.Amyloidosis: is a cure possible?N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.Transplantation vs. conventional-dose therapy for amyloidosis.Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.Light chain amyloidosis 2012: a new era.Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia.Systemic amyloidoses: what an internist should know.Biochemical markers in early diagnosis and management of systemic amyloidoses.Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis.Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.End-stage renal failure due to amyloidosis and recurrent fever on dialysis--is there a link?First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome.
P50
Q26829735-2A797237-FDEC-4523-889C-28FCCF5549FCQ28069975-40DB9549-D346-4ABF-8F7B-4A5329727C98Q30570936-BFF96A3C-EAF0-4B13-A67C-90DBA38CE20FQ31107571-3EB9CECD-9096-4ABE-8FDD-8105C63B8F73Q33166570-7368B2E3-14E8-41CD-98F9-CFE8A05B65A3Q33370210-A8828074-136C-4A3C-9445-F54DA151752CQ33718805-8AE3E72E-0D33-4D71-ACB4-8C8EE72A7667Q34140093-78C60D38-EC57-4FE6-9722-52620D44FB1AQ34311781-044CA801-2553-4DDA-9BF5-DC9458C05DA4Q34353682-82397FB4-9195-4085-9A40-B7BDC8BBEFCEQ35002777-9E8C20F8-F6B2-491D-B684-0179B696F3CBQ35006134-A0F2FC8F-9033-4459-A292-A9F658CED95CQ36274065-E06C4A6D-1C4D-4F81-BC6E-4AB49F10EDBAQ36282399-C3119ABD-3DCA-4BAD-9E0D-99D74F5743B0Q36801112-1C875987-4A09-49FD-85B4-15102116DC67Q36862339-0087A794-1A9F-43B2-8793-6750762CF703Q37061542-514F10AC-24B5-4681-96CF-D23E40B45EF4Q37179896-7793E9F1-5EA4-45EF-B8DA-2143F345FA47Q37456396-DC7937DD-395B-4945-B91C-4CA3F63D3C69Q37676296-3908EA95-9E65-492C-9F3A-90C253A18BB5Q37823132-75DDF78F-7C8C-426E-9773-C350D0D4438AQ37999957-A3E983AC-D2B6-40F1-85AF-CEB7BFBEEA3FQ38072108-B4444500-1FC9-406E-9311-C04D9FC050C8Q38087775-FB956627-0560-4DAA-896F-0FFC3720A0BDQ38164896-207CA39C-1ABD-4201-ABC2-7680DAF2F95BQ38215594-2B746186-27C1-4028-A0C2-4CDFF6B66D16Q38406601-3E51127D-7AD3-4ACB-BE12-65A59EE73247Q38414834-5B2588E5-5DBD-44D1-9949-E1DA39077FE5Q38614967-634F8678-3573-45D9-99BA-40830E9238F1Q38911216-BE141158-8F39-4C73-A7E7-76E61EA49031Q39063150-9B9F18F1-B08E-40BE-A34B-D25948F95426Q39166716-F7B7E336-86D4-4832-90CC-DB43E14C8C93Q39343666-1005E066-00E6-4AD4-9FDF-43962A6B3AD0Q39821908-69B2B83D-6A25-4919-B1A2-11526C3C9422Q40134213-9D05D1D2-91AE-4C1A-A1E9-F02076D74C82Q40183492-DEA8D37E-541B-4F5D-9763-23910943E35FQ40184707-B66623AF-92B9-4F65-A104-D964AACD3071Q40355511-044801C2-B762-4025-91D7-20EB7B8EE26FQ40415660-2662DEE9-A669-433A-9AB0-F6DE6EC818F0Q40524789-23F76195-40D0-4741-9322-CB9745D619E8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Giovanni Palladini
@ast
Giovanni Palladini
@en
Giovanni Palladini
@es
Giovanni Palladini
@nl
Giovanni Palladini
@sl
type
label
Giovanni Palladini
@ast
Giovanni Palladini
@en
Giovanni Palladini
@es
Giovanni Palladini
@nl
Giovanni Palladini
@sl
prefLabel
Giovanni Palladini
@ast
Giovanni Palladini
@en
Giovanni Palladini
@es
Giovanni Palladini
@nl
Giovanni Palladini
@sl
P108
P1053
G-1763-2010
P106
P1153
7006442443
P21
P214
14152820193300682609
P31
P3829
P496
0000-0001-5994-5138
P734
P735
P7859
viaf-14152820193300682609